2019
1188PD Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis
Catenacci D, Park H, Uronis H, Kang Y, Ng M, Enzinger P, Lee K, Lim K, Gold P, Lacy J, Park S, Huber K, Wynter-Horton A, Nordstrom J, Wu T, Wigginton J, Baughman J, Rosales M, Davidson-Moncada J, Bang Y. 1188PD Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis. Annals Of Oncology 2019, 30: v484-v485. DOI: 10.1093/annonc/mdz253.014.Peer-Reviewed Original ResearchMedian progression-free survivalMedian overall survivalGenentech/RocheBristol-Myers SquibbGastroesophageal adenocarcinomaPD-L1Prime TherapeuticsOno PharmaceuticalOS ratesEMD SeronoMerck SeronoAstellas PharmaDaiichi SankyoGilead SciencesChemotherapy-free regimenPD-L1 CPSProgression-free survivalTreatment of patientsCancer ptsGuardant HealthMedian followMedian PFSCheckpoint inhibitorsExpansion cohortAcceptable tolerabilityAntitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).
Catenacci D, Lim K, Uronis H, Kang Y, Ng M, Gold P, Enzinger P, Lee K, Lacy J, Park H, Yen J, Odegaard J, Franovic A, Baughman J, Wynter-Horton A, Chen F, Moore P, Wu T, Davidson-Moncada J, Bang Y. Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC). Journal Of Clinical Oncology 2019, 37: 65-65. DOI: 10.1200/jco.2019.37.4_suppl.65.Peer-Reviewed Original ResearchDisease control rateObjective response ratePD-L1 expressionGastric carcinomaHER2 expressionHigh PD-L1 expressionStandard first-line therapyTumor PD-L1 expressionChemo-free regimenDrug-related SAEsFirst-line therapyProgression-free survivalAnti-HER2 agentsAutoimmune hepatitisExploratory endpointsMedian overallDiabetic ketoacidosisAcceptable tolerabilityAdvanced HER2Adverse eventsPD-L1Control rateIHC 3Grade 3Archival tumors
2018
Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).
Catenacci D, Park H, Uronis H, Kang Y, Lacy J, Enzinger P, Park S, Lee K, Ng M, Gold P, Yen J, Franovic A, Kelly R, Wynter-Horton A, Li D, Muth J, Baughman J, Hong S, Davidson-Moncada J, Bang Y. Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). Journal Of Clinical Oncology 2018, 36: 4030-4030. DOI: 10.1200/jco.2018.36.15_suppl.4030.Peer-Reviewed Original ResearchPD-L1